AbCellera appoints Lyell CEO Lynn Seely to board as independent director

AbCellera Biologics, Inc.
Lyell Immunopharma, Inc.

AbCellera Biologics, Inc.

ABCL

0.00

Lyell Immunopharma, Inc.

LYEL

0.00
  • AbCellera appointed Lynn Seely, M.D., to its board as an independent director.
  • Seely is president and CEO of Lyell Immunopharma, focused on next-generation CAR T-cell therapies for hematologic malignancies and solid tumors.
  • She previously led Myovant Sciences as president and CEO, overseeing commercialization of Myfembree and Orgovyx.
  • Seely was chief medical officer at Medivation, leading development of Xtandi through global approvals before Pfizer’s USD 14 billion acquisition.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260706393691) on July 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.